---
title: Reduce Parkinson progression with antiinflammatory
nct_id: NCT07370532
phase: PHASE2
status: RECRUITING
sponsor: Ihab Elsayed Hassan
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07370532"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07370532"
last_fetched: "2026-05-10T14:04:20.516Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce Parkinson progression with antiinflammatory

**Goal (in five words):** Reduce Parkinson progression with antiinflammatory

**Official Title:** Clinical Study to Evaluate Safety and Efficacy of Etoricoxib in Patients With Parkinson's Disease Treated With Conventional Treatment

**Trial ID:** [NCT07370532](https://clinicaltrials.gov/study/NCT07370532)

## Key Facts

- **Phase:** PHASE2
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Ihab Elsayed Hassan
- **Target Enrollment:** 60 participants
- **Start Date:** 2026-01-30
- **Completion Date:** 2027-11-10
- **Conditions:** Parkinson Disease
- **Interventions:** L-dopa, Etoricoxib
- **Intervention Types:** DRUG

## Summary For Families

Researchers are testing whether adding etoricoxib, a selective COX-2 anti-inflammatory, to usual levodopa care is safe and may help by reducing the inflammation that might contribute to neuron damage and symptom worsening in Parkinson's. Etoricoxib works by blocking the COX-2 enzyme and lowering prostaglandin-driven inflammation; it does not boost dopamine like levodopa, but by reducing inflammatory stress it could protect neurons or slow decline, and the study will watch for safety and interactions with standard Parkinson's drugs. The trial plans to enroll about 60 people aged 50 to 70 with Parkinson's diagnosed using the UPDRS who are on conventional treatment. People who are pregnant or breastfeeding, have significant liver or kidney problems, current use of other anti-inflammatory drugs, substance abuse, or known allergy to the medications are excluded.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 70 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Age ≥ 18 years.
* Both male and female will be included.
* Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.

Exclusion Criteria:

* Breast feeding
* Patients with significant liver and kidney function abnormalities.
* Alcohol and / or drug abusers.
* Patients with known allergy to the study medications
* Pregnant women and women with planned pregnancy.
* Patients who are currently using other anti-inflammatory drugs.
```

## Locations (1)

- Mansoura University, Al Mansurah, Egypt _(31.0364, 31.3807)_
  - Ehab Hassan, PhD — (CONTACT) — 01067831661 — Ehassan@horus.edu.eg

---

*Canonical: https://parkinsonspathways.com/trial/NCT07370532*  
*HTML version: https://parkinsonspathways.com/trial/NCT07370532*  
*Source data: https://clinicaltrials.gov/study/NCT07370532*